R. Martin-Santos, C. Bartrés, L. Nacar, R. Navinés, M. Cavero, S. Lens, S. Rodriguez-Tajes, J.C. Pariante, I. Horrillo, E. Muñoz-Moreno, N. Bargallo, L. Capuron, J. Meana, X. Forns, and Z. Mariño
Introduction Chronic Hepatitis C infection is considered a systemic disease with extrahepatic manifestations, mainly neuropsychiatric symptoms, which is associated with a chronic low-grade inflammatory state. Hepatitis C virus (HCV) eradication is currently achieved in >98% of cases with oral direct-acting antivirals (DAA). Objectives To study potential clinical neuropsychiatric changes (mood, cognition, sleep, gastrointestinal, sickness, and motion) in HCV-infected patients after HCV eradication with DAA. Methods Design: Cohort study. Subjects: 37 HCV-infected patients, aged